Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04353414
Other study ID # 20-00058
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 1, 2020
Est. completion date February 23, 2022

Study information

Verified date February 2022
Source NYU Langone Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to compare two different treatment options on their effectiveness to reduce post-operative pain, narcotic (opioid pain medication) usage and recovery time in patients undergoing primary hip arthroscopy surgery. The first treatment option is a Transmuscular Quadratus Lumborum (TQL) block plus hip incision site (Pericapsular) Injection. The TQL block is an ultrasound guided injection between the quadratus lumborum and the psoas muscles in the back. The anesthesiologist will perform the TQL block The second treatment option is only a hip incision site (Pericapsular) Injection. In this group, the surgeon will inject local anesthetic into the incision or hip portal sites to decrease sensation.


Description:

This is a phase IV, randomized, single-blind, single-center study comparing postoperative pain, opioid usage and Post-Anesthesia Care Unit (PACU) recovery time for patients who receive a Transmuscular Quadratus Lumborum block (TQLB) plus pericapsular injection versus pericapsular injection (PCI) undergoing primary hip arthroscopy.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date February 23, 2022
Est. primary completion date February 17, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients between 18 and 65 years of age - Patients undergoing Primary Hip Arthroscopy - Patients diagnosed with femoroacetabular impingement (FAI) - Patients who consent to be randomized. Exclusion Criteria: - Patients younger than 18 and older than 65; - Patients with a history of chronic pain that have used opioids for pain management for 3 months or longer; - Patients with diagnosed or self-reported cognitive dysfunction; - Patients with a history of neurologic disorder that can interfere with pain sensation; - Patients with a history of drug or recorded alcohol abuse; - Patients who are unable to understand or follow instructions; - Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease; - Patients with an allergy or contraindication to any of the medications used in the study, or patients with a contraindication to any study procedures; - Patients with BMI over 40; - Any patient that the investigators feel cannot comply with all study related procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Transmuscular Quadratus Lumborum Block
Transmuscular Quadratus Lumborum Block (TQLB) is a relatively new block that targets thoracic and lumbar nerves. The decrease in sensation means a decrease in pain. The TQL block will be preformed in addition to an incision-site injection (on hip), called pericapsular injection. The potential risks associated with the Transmuscular Quadratus Lumborum Block (TQLB) include nerve damage and infection at injection site. In addition, there can be temporary sensory and motor loss, depending on the dosage, site of injection and duration of the nerve block. However, the amount (30mL) used in this study meets FDA dosage-regulations for this medication.
Pericapsular injection
Pericapsular injection (PCI) of 20 mL of 0.25% Bupivacaine HCL (numbing medication) into the incision-site (hip portal sites) to decrease sensation. The potential risks associated with the pericapsular injection include bleeding, infection at injection site and local anesthetic toxicity however, the likelihood is low due to the expertise of the surgeon preforming the injection and the sterile environment and good clinical practice from clinicians, which reduces the likelihood of infection.
Drug:
Bupivacaine Hydrochloride
Bupivacaine used for this study is the standard of care for both TQLB and PCI. Pericapsular injection (PCI) contains 10 mL of 0.25% Bupivacaine HCL which will be injected through the anterolateral portal while the additional 10 mL will be injected through the mid-anterior portal.

Locations

Country Name City State
United States NYU Langone Health New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comparison of post-operative pain as per the Visual Analogue Scale (VAS) This will be measured by using Visual Analogue Scale (VAS) pain scores and compared between the 2 treatment groups after surgery. The distribution of pain Visual Analogue Scale (VAS) scores in post- surgical patients will describe their postoperative pain intensity as none, mild, moderate, or severe, the following cut points on the pain Visual Analogue Scale (VAS) have been recommended: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm). 1 Day of surgery
Primary Comparison of post-operative pain as per the McGill pain scores This will be determined by the McGill Pain questionnaire (MPQ) scores and compared between the 2 treatment groups during the post-operative period. The MPQ assesses three separate components of the pain experience: the sensory intensity, the emotional impact and the cognitive evaluation of pain. Each descriptor is ranked on a 0 ("none") to 3 ("severe") intensity scale. 1 Day of surgery
Secondary Use of Opioids by participants This will be assessed by the pain medications given to the participants depending on their pain level. 1 Day of surgery
Secondary Comparison in Post-Anesthesia Care Unit (PACU) Phase 1 recovery time by treatment group This will be an observation of the time it takes the patient in the immediate post op period to transition to Phase II. Factors such as severe pain and post op nausea and vomiting may affect a patient's Phase I recovery time so the study want to compare this parameter between both treatment groups. 1 Day of surgery
See also
  Status Clinical Trial Phase
Completed NCT03590145 - Reliability of the Doha Agreement Classification of Groin Pain
Completed NCT06083428 - Erector Spinae vs. PENG Block for Total Hip Arthroplasty Phase 4
Completed NCT05551000 - Functional Training to Improve Everyday Performance in Elderlies N/A
Completed NCT04289922 - Validation of the Norwegian VISA-G Questionnaire
Recruiting NCT05868369 - The Effectiveness of Immersive Virtual Reality as a Pain Control Modality After Hip Arthroscopy N/A
Completed NCT04211987 - Fast Track Total Hip Arthroplasty vs Standard Care N/A
Recruiting NCT04736641 - Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Japanese Orthopaedic Association Hip Disease Evaluation Questionnaire
Completed NCT02947178 - Hip Arthroscopy Pain Control Randomized Control Trial (RCT) Phase 4
Recruiting NCT03985280 - Radiofrequency Versus Intraarticular Local Anesthestic and Steroids Injection for Chronic Hip Pain. Phase 4
Completed NCT05944380 - PENG Block for Total Hip Arthroplasty Phase 4
Completed NCT05261009 - PENG Block Versus LP Block for THA Postop Pain Phase 4
Recruiting NCT05022381 - Treatment of Chronic Hip Pain by Application of Conventional Radiofrequency Thermocoagulation to the Articular Branches of the Femoral and Obturatory Nerve N/A
Recruiting NCT05853640 - Education and Exercise for Patients With Longstanding Hip and Groin Pain N/A
Completed NCT03248934 - Patient Performed Examination for Patients With Intra-articular Hip Pain N/A
Completed NCT03720821 - Cognitive Flexibility Training for Persistent Pain: Neuroimaging Pilot (COFLEX-i) N/A
Completed NCT04393909 - Improving Safety of Diagnosis and Therapy in the Inpatient Setting N/A
Recruiting NCT04027140 - MDR - M/L Taper With Kinectiv Technology Stems and Necks
Recruiting NCT03490071 - Long-term Follow up of Patients With Longstanding Hip and Groin Pain
Recruiting NCT04028687 - MDR - PMCF Study for Taperloc Complete Stems
Recruiting NCT03576625 - Effect of Buglossoides Oil on Recent Chronic Non-injurious Hip and Knee Pain Phase 1